Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 2, 2023
The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injectionPolyzois Makras, Maria P Yavropoulou, Stergios A Polyzos, et al.
Acta Bio-Medica : Atenei Parmensis|October 27, 2022
Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisitedMaria P Yavropoulou, Athanasios D Anastasilakis, Ploutarchos Tzoulis, et al.
Oxidative Medicine and Cellular Longevity|May 19, 2016
Role of Vanadium in Cellular and Molecular Immunology: Association with Immune-Related Inflammation and Pharmacotoxicology MechanismsOlga Tsave, Savvas Petanidis, Efrosini Kioseoglou, et al.
European Journal of Endocrinology|March 12, 2017
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatmentAthanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, et al.
Cytokine|May 11, 2010
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek populationPeristera Paschou, Asterios Kukuvitis, Maria P Yavropoulou, et al.
Bone Reports|September 20, 2021
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patientsPolyzois Makras, Panagiotis Petrikkos, Athanasios D Anastasilakis, et al.
Endocrinology, Diabetes & Metabolism Case Reports|February 1, 2019
Hypercalcitoninaemia in pseudohypo-parathyroidism type 1A and type 1BMaria P Yavropoulou, Efstathios Chronopoulos, George Trovas, et al.
European Journal of Endocrinology|June 28, 2024
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?Athanasios D Anastasilakis, Maria P Yavropoulou, Andrea Palermo, et al.
Hemoglobin|April 5, 2017
Insulin Secretion and Resistance in Normoglycemic Patients with Sickle Cell DiseaseMaria P Yavropoulou, Maria Pikilidou, Despoina Pantelidou, et al.
Frontiers in Endocrinology|March 16, 2026
Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic miceVagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, et al.
Pageof 12